

IAPS Rec'd PCT/PCTO 16 DEC 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Rachel Schneerson et al.**Application No.:** To be assigned**Filed:** Herewith**Confirmation No.:** To be assigned**For:** POLY-GAMMA-GLUTAMIC
CONJUGATES FOR ELICITING IMMUNE
RESPONSES DIRECTED AGAINST
BACILLI**Examiner:** To be assigned**Art Unit:** To be assigned**Attorney Reference No.:** 4239-68226-07**CERTIFICATE OF EXPRESS MAILING**

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as Express Mail Label No. EV669611808US in an envelope addressed to: MAIL STOP PCT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent
for Applicant(s)Date Mailed December 2, 2005

MAIL STOP PCT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(2)

Listed on the accompanying Form PTO-1449 are several English-language documents.

Copies of the non-U.S. references are enclosed. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement (“IDS”) within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this IDS is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 
Wayne W. Rupert
Registration No. 34,420

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	4239-68226-07
	Application Number	To be assigned (825)
	Filing Date	Herewith
	First Named Inventor	Rachel Schneerson
	Art Unit	To be assigned
	Examiner Name	To be assigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		4,496,538	29 Jan 1985	Gordon et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO/PCT	WO 01/60412 A2	23 Aug 2001	Genzyme Corp.

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Alkan et al., "Antigen recognition and the immune response: The Capacity of L-tyrosine-azobenzeneearsonate to serve as a carrier for a macromolecular hapten," <i>Journal of Immunology</i> 107(2):353-358, 1971
		Devi et al., " <i>Cryptococcus-neoformans</i> Serotype A Glucuronoxylomannan-Protein Conjugate Vaccines: Synthesis, Characterization and Immunogenicity," <i>Infection and Immunity</i> 59(10):3700-3707, 1991
		Emmanuel et al., "Poly-gamma-D-glutamic acid as a template for functionalized water-soluble biomaterials," <i>Abstracts of Papers American Chemical Society</i> 219(1-2):BIOL 133, 2000, and 219 th Meeting of the American Chemical Society, San Francisco, California, March 26-30, 2000

EXAMINER SIGNATURE:	DATE CONSIDERED:
---------------------	---------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

Attorney Docket Number	4239-68226-07
Application Number	10/559825 To be assigned
Filing Date	Herewith
First Named Inventor	Rachel Schneerson
Art Unit	To be assigned
Examiner Name	To be assigned

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
		Goodman et al., "Immunochemical Studies on the Poly-gamma-D-glutamyl Capsule of <i>Bacillus anthracis</i> . 3. The Activity with Rabbit Antisera of Peptides Derived from the Homologous Polypeptide" <i>Biochemistry</i> 7(2):706-710, 1968
		King et al., "Preparation of Protein Conjugates via Intermolecular Hydrazone Linkage," <i>Biochemistry</i> 25:5774-5779, 1986
		Klaus et al., "The immunological properties of haptens coupled to thymus-independent carrier molecules: III. The role of the immunogenicity and mitogenicity of the carrier in the induction of primary IgM anti-hapten responses," <i>European Journal of Immunology</i> 5(2):105-111, 1975
		Leppla et al., "Development of an improved vaccine for anthrax," <i>Journal of Clinical Investigation</i> 110(2):141-144, 2002
		Pannifer et al., "Crystal structure of the anthrax legal factor," <i>Nature</i> 414:229-233, 2001
		Pozsgay et al., "Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from <i>Shigella dysenteriae</i> type 1," <i>Proc. Natl. Acad. Sci. USA</i> 96:5194-5197, 1999
		Ramirez et al., "Production, recovery and immunogenicity of the protective antigen from a recombinant strain of <i>Bacillus anthracis</i> ," <i>Journal of Industrial Microbiology and Biotechnology</i> 28:232-238, 2002
		Rhie et al., "A dually active anthrax vaccine that confers protection against both Bacilli and toxins," <i>PNAS</i> 100(19):10925-10930, 2003
		Robbins et al., "Prevention of Systemic Infections, Especially Meningitis, Caused by <i>Haemophilus influenzae</i> Type b," <i>JAMA</i> 276(14):1181-1185, 1996
		Schneerson et al., "Preparation, Characterization, and Immunogenicity of <i>Haemophilus influenzae</i> Type b Polysaccharide-protein Conjugates," <i>Journal of Experimental Medicine</i> 152(2):361-376, 1980
		Schneerson et al., "Poly(gamma-D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of <i>Bacillus anthracis</i> : A potential addition to the anthrax vaccine," <i>PNAS</i> 100(15):8945-8950, 2003
		Senyk et al., "Immune response to glucagons in conjugated form," <i>Immunochemistry</i> 9(2):97-110, 1972
		Shinefield et al., "Use of a <i>Staphylococcus Aureus</i> Conjugate Vaccine in Patients Receiving Hemodialysis," <i>The New England Journal of Medicine</i> 346:491-496, 2002

EXAMINER SIGNATURE:	DATE CONSIDERED:
---------------------	---------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-68226-07
Application Number	To be assigned
Filing Date	Herewith
First Named Inventor	Rachel Schneerson
Art Unit	To be assigned
Examiner Name	To be assigned

EXAMINER SIGNATURE:	DATE CONSIDERED:
------------------------	---------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.